Drug Profile

APO 010

Alternative Names: APO-010

Latest Information Update: 08 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Apoxis
Developer Allarity Therapeutics; Valerio Therapeutics
Class Antineoplastics; Recombinant fusion proteins; Tumour necrosis factors
Mechanism of Action Apoptosis stimulants; CD95 antigen stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I/II Multiple myeloma
Discontinued Haematological malignancies; Solid tumours

Most Recent Events

22 Apr 2021 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Second-line therapy or greater) in Switzerland (IV)
22 Apr 2021 Discontinued - Preclinical for Haematological malignancies in Switzerland (IV)
07 Oct 2020 Oncology Venture A/S is now called Allarity Therapeutics

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com